Cancer Center Administration undertakes a range of activities essential to maximizing the effectiveness of CCSG-supported infrastructure and adding value to the UC Davis cancer research enterprise and the integrated cancer program with the Lawrence Livermore National Laboratory (LLNL). Administration oversight of CCSG expenditures ensures that they are used only in the ways specified by NCI Guidelines and the proposal for competitive renewal of NCI designation. Activities encompass support for scientific programs and collaborations, membership, shared resources, developmental funds used for pilot studies, recruitment and developing shared resources, clinical trial data management, and leadership organizations. The Administration adds value to the cancer research effort by planning and organizing "Cross Talk" meetings, cancer biology seminars, an annual research symposium, and various collaborative conferences targeting Initiatives In breast cancer, Inflammation, stem cells, Imaging, brain tumors, and key research communities at UC Davis and LLNL. In addition, Administration is responsible for the coordination of Cancer Center membership, the Cancer Center Web site (http://cancer.ucdmc.ucdavis.edu), and various list serves and communication tools. Central operations, fiscal affairs, contract and grant administration, purchasing, event planning, proposal development, and public affairs are other core services provided by Cancer Center Administration to the Director, senior leaders and to the membership at large to advance strategic plans, new areas of research, and team science.

Public Health Relevance

Administration maintains the research organization and data about the research organization, provides staff expertise in financial management, grant proposal development scientific meeting development internal and external relations of significance to the research enterprise, and modern forms of electronic communication such as list servers and the Internet. In these ways. It builds the scope of cancer research at UCD.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-11
Application #
8741013
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$241,017
Indirect Cost
$84,020
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24
Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24
Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4
Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9
Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6
Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25
Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8
Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49
Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40
Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6

Showing the most recent 10 out of 84 publications